



Case Report

Focal epilepsy features in a child with Congenital Zika Syndrome

Piumi Jayatilake^a, Vivian Oyegunle^a, Randall Waechter^{a,b}, Barbara Landon^b, Michelle Fernandes^c, Nikita Cudjoe^b, Roberta Evans^b, Trevor Noël^b, Calum Macpherson^b, Tyhiesia Donald^d, Samah G. Abdelbaki^e, Kesava Mandalaneni^a, Dennis Dlugos^f, Geetha Chari^g, Archana A. Patel^h, Elyse N. Grossi-Soysterⁱ, A. Desiree LaBeaudⁱ, Karen Blackmon^{b,j,*}

^a St. George's University, St. George's, West Indies, Grenada

^b Windward Islands Research and Education Foundation, St George's University, West Indies, Grenada

^c Faculty of Medicine, Department of Paediatrics, University of Southampton, Southampton, UK

^d Ministry of Health, Government of Grenada, West Indies, Grenada

^e Biosignal Group Inc., Acton, MA, USA

^f Children's Hospital of Pennsylvania, Philadelphia, PA, USA

^g SUNY Downstate Health Sciences University, New York, NY, USA

^h Boston Children's Hospital, Division of Epilepsy and Clinical Neurophysiology, Boston, MA, USA

ⁱ Stanford University School of Medicine, Department of Pediatrics, CA, USA

^j Mayo Clinic, Jacksonville, FL, USA



ARTICLE INFO

Article history:

Received 30 August 2020

Revised 3 November 2020

Accepted 8 November 2020

Available online 25 November 2020

Keywords:

Congenital Zika Syndrome (CZS)

Microcephaly

Focal Epilepsy

Electroencephalography (EEG)

Telemedicine

ABSTRACT

Zika virus (ZIKV) is a mosquito-borne, single-stranded DNA flavivirus that is teratogenic and neurotropic. Similar to the teratogenic effects of other TORCH infections, ZIKV infection during pregnancy can have an adverse impact on fetal and neonatal development. Epilepsy is detected in 48–96% of children with Congenital Zika Syndrome (CZS) and microcephaly. Early epilepsy surveillance is needed in children with prenatal ZIKV exposure; yet, most ZIKV-endemic regions do not have specialist epilepsy care. Here, we describe the demographic, clinical, imaging, and EEG characteristics of a 2-year-old child with CZS and microcephaly who presented with focal epileptiform activity, suboptimal growth, and severe neurodevelopmental delays. Administration of a brief seizure questionnaire by allied health professionals to the patient's caregiver helped to characterize the child's seizure semiology and differentiate focal from generalized seizure features. A telemedicine EEG interpretation platform provided valuable diagnostic information for the patient's local pediatrician to integrate into her treatment plan. This case illustrates that CZS can present with focal epilepsy features and that a telemedicine approach can be used to bridge the gap between epilepsy specialists and local care providers in resource limited ZIKV-endemic regions to achieve better seizure control in children with CZS.

© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Zika virus (ZIKV) is a mosquito-borne, single-stranded DNA flavivirus that is teratogenic and neurotropic [1]. ZIKV in pregnant women can infect the fetus through vertical transmission, particularly in the first trimester before a protective zone of mature villous trophoblasts has been established in the uteroplacental circulatory system [2–4]. After crossing the placental barrier, ZIKV directly targets neural progenitor cells, which can lead to cell cycle

dysregulation, cell cycle arrest, and apoptosis [5]. Similar to the teratogenic effects of other TORCH infections, ZIKV infection during pregnancy can have a substantial negative impact on fetal and neonatal brain development, which increases epilepsy risk [6]. Congenital Zika Syndrome (CZS) is characterized by severe microcephaly, thin cerebral cortices with subcortical calcifications, macular scarring and focal pigmentary retinal mottling, congenital contractures, and marked early hypertonia and symptoms of extrapyramidal involvement [7]. Focal brain malformations can be found concurrent with microcephaly and in the absence of microcephaly [8]; these include focal cortical dysplasia, polymicrogyria, decreased frontal lobe mass, and/or calcifications within the basal ganglia [4,8]. Epilepsy is detected in 48–96% of children

* Corresponding author at: Mayo Clinic Department of Psychiatry and Psychology, 4500 San Pablo Road, Jacksonville, FL 32224, USA.

E-mail address: blackmon.karen@mayo.edu (K. Blackmon).

with CZS and microcephaly [9–13]. Epilepsy rates are substantially lower in normocephalic children with prenatal ZIKV exposure (3%), although still elevated relative to the general population [14].

Early diagnosis and treatment of epilepsy is essential in CZS, as seizures can predispose children to a lifetime of neurodevelopmental and social deficits [15]. Language and motor delays are commonly found in children with ZIKV-associated epilepsy [16,17], which may necessitate intensive early intervention services. In children with CZS and microcephaly, seizure onset is typically within the first few months of life [12,13]. Electroencephalographic (EEG) findings include abnormal background rhythms, hypsarhythmia, and focal or multifocal epileptiform discharges [12]. Given that CZS may be associated with generalized, focal, or mixed seizures, EEG is essential for guiding treatment. However, most ZIKV-endemic regions do not have access to EEG or epilepsy specialist care [18]. Here, we introduce a telemedicine approach to epilepsy care that can be used to bridge the gap between epilepsy specialists and local pediatricians in ZIKV-endemic regions. We describe how this approach augmented the care and treatment of a 2-year-old child with CZS and microcephaly.

2. Case report

A two-year-old Afro-Caribbean female presented with microcephaly during a ZIKV outbreak in Grenada, West Indies. Her mother was recruited from a public health center as part of a larger study investigating the impact of *in utero* Zika virus exposure on neurodevelopment [14]. The mother provided written informed consent to support her child’s participation in the study and also consented to publication of this case study.

2.1. Serum testing

The mother had serum drawn at 24 (±2) weeks gestation. Prenatal serology was positive for flavivirus and negative for alphavirus infection using IgM antibody captured enzyme-linked immunosorbent assay (MAC-ELISA) [19]. A plasmonic-gold (pGOLD) platform (Nirmidas Biotech, Palo Alto, CA) for measuring IgG against ZIKV and dengue virus (DENV) antigens was used to distinguish these possible flaviviral infections, with IgG avidity used to determine the timing of exposure [20]. The pGOLD IgG immunoassay has demonstrated sensitivity and specificity to ZIKV greater than 90% and 98%, respectively, in the convalescent phase [20]. Maternal pGOLD IgG immunoassay results were positive for ZIKV and DENV antibodies. IgG avidity testing showed ZIKV exposure within the prior 6 months and more remote DENV infection (i.e., prior to pregnancy). The infant had serum drawn at 2 months of age. Results from the pGOLD IgG immunoassay were positive for ZIKV and negative for DENV.

2.2. Birth and delivery

The mother was 30 years of age at the time of delivery. Her pregnancy was uncomplicated, with no reported alcohol, drug, or tobacco use. The patient was born full-term via normal vaginal delivery. Meconium aspiration was noted and resuscitative assistance was provided. One-minute APGAR score was 2, 5-minute score was 3, and 10-minute score was 8. Facial dysmorphism was observed. Head circumference was 30 cm at birth ($z = -3.5$) [23]. Reflex testing was performed at 2 months of age with grasping, sucking, and plantar reflexes present and Moro and Galant reflexes absent.

2.3. Growth and development

Suboptimal growth was observed on serial anthropometric assessments (Fig. 1) using WHO standards [21]. A neurological exam was performed at 16 months of age. Strabismus was observed. Babinski reflex was present. Motor examination showed significant global hyperreflexia and global hypertonia, which were more pronounced in the left upper and lower limbs. The Intergrowth-21st Neurodevelopmental Assessment (INTER-NDA) package was used to assess vision, motor functions, language skills, cognitive skills, and social/behavioral functions at 24 months of age [22]. Her scores across all domains were in the profoundly delayed range (<3rd percentile), with skills at approximately the level of a 5-month-old. She was unable to visually track or reach for objects but could hold her head up in prone position and was able to emotionally respond to faces.

2.4. Neuroimaging

Computed tomography (CT) and magnetic resonance imaging (MRI) of the brain were clinically acquired at 13 months and showed dilation of ventricles, with more pronounced volume loss in the right hemisphere, particularly in the frontoparietal lobes, as well as lissencephaly and agyria, predominantly in the frontal lobes (Fig. 2A–C).

2.5. Epilepsy profile

The patient has no known family history of epilepsy. Seizure onset was at 3 months of age. She was diagnosed with epilepsy based on the presence of at least 2 unprovoked seizures occurring more than 24 hours apart and started on carbamazepine (10 mg/kg/day) [23]. Her mother described features of the patient’s seizures with prompting from the Pediatric Epilepsy Screening Questionnaire (PESQ), a screening tool used to identify seizures and distinguish focal from generalized features in resource-limited settings [24]. The PESQ was administered at 15, 24, and 27 months of age by allied health research staff in the patient’s local health center. At 15 months, the patient’s mother reported non-motor (behavioral arrest/staring spells) and motor (tonic-clonic) seizures of unknown onset that were occurring at a frequency of one to three times weekly, with a maximum of three episodes in a day. This was communicated to her local pediatrician and her dosage of carbamazepine was increased to 25 mg/kg/day. Serum concentrations were not acquired because this service was not locally available. She had a period of seizure freedom for several months. At




Fig. 1. Serial anthropometric assessment. Head circumference (HC), weight, and height were standardized for age using World Health Organization growth charts. Head circumference remains well below normal limits for age. Weight remains within normal limits at 2 and 15 months but declines to the lower end of the normal range by the age of 24 months. Length remains at the lower end of the normal range from 2 to 24 months.




Fig. 2. Magnetic resonance imaging (MRI) at 13 months (A–C). A: FLAIR axial view demonstrating enlarged lateral ventricles, predominantly in the right hemisphere. B: T1-weighted mid-sagittal view demonstrating intact corpus callosum and brain stem. C: T2-weighted coronal view demonstrating enlarged lateral ventricles and reduced cerebral volume, predominantly in the right hemisphere. D: Electroencephalography (EEG) at 16 months showing focal slowing (arrows) in left hemisphere.

27 months, her mother reported a cluster of breakthrough focal to bilateral tonic-clonic seizures (shaking of one side only at onset), which was communicated to the patient’s pediatrician. She was transitioned to levetiracetam (two doses of 10 mg/kg/day). Good seizure control was achieved and maintained as of 36 months of age.

2.6. Telemedicine electroencephalography (TeleEEG)

As part of a research epilepsy surveillance protocol [14], we utilized the microEEG® (www.biosignalgroup.com) monitoring system. This 26-channel system has been validated in newborns [25] and was designed for use in field applications and high-noise environments [26–28]. It is optimized for use with the Eze-Net headpiece, which conforms to the International 10/20 System. The headpiece was easy to apply by trained allied health research staff and was well tolerated by the patient. We recorded electrophysiological activity during wake and sleep states for a minimum of 20 min along with a video recording of patient behavior time-locked to the EEG recording. EEG data were transferred to a HIPAA compliant server for remote interpretation by 3 pediatric epileptologists (DD, GC, AP), using a standardized form. EEGs acquired at 15,

16, and 24 months showed bilateral, focal epileptiform activity in frontal regions and focal slowing in the left frontal region (Fig. 2D). No generalized epileptiform findings were present in any of the EEGs. These findings were communicated to the patient’s local pediatrician.

3. Discussion

This case study illustrates how the diagnosis and treatment of a child with CZS and focal epilepsy were improved by the use of a seizure questionnaire and teleEEG platform in a resource-limited region. Epilepsy profiles in CZS are diverse [12]. The mechanisms by which prenatal ZIKV infection predisposes a child to seizures are not yet fully understood but have been investigated in mouse models, human stem cells, and cerebral organoids [29–30]. ZIKV initially targets astrocytes [29], a type of glial cell, in addition to targeting neuronal progenitor cells [30]. The virus reacts with the tips of glial processes of astrocytes primarily in the cortex, hippocampus, thalamus, and hypothalamus [29]. During later stages of infection, astrocytes release viral progeny, resulting in further spread in localized regions [29]. Additionally, through its induction

of cell death of neuronal progenitor cells, ZIKV can lead to cortical thinning and reduction of brain volume on neuroimaging [8,30]. These findings indicate that focal, potentially epileptogenic, brain malformations often co-occur with globally abnormal morphology. Our patient presented with more pronounced volume loss in the right hemisphere, and focal lissencephaly and agyria in the right anterior region, which raises the possibility of greater astrocytic release of viral progeny in anterior regions during critical stages of her prenatal cortical development.

Access to EEG and specialist epilepsy care is limited in many ZIKV-endemic regions [18], yet neurophysiological studies can provide valuable information to localize epileptiform activity and assist with differential diagnosis of a focal versus generalized epilepsy syndrome. The teleEEG platform that we utilized provided valuable clinical information for the patient's local pediatrician (TD) to integrate into her diagnosis and treatment plan and may be similarly accessible to non-specialty clinics in resource-limited regions, as long as there is a remote/virtual relationship with a consulting epileptologist. Use of a formal epilepsy questionnaire helped to prompt communication of seizure semiology and medication failures to the patient's physician. The questionnaire we utilized was developed for use in resource-limited regions and designed to be administered by non-specialist allied health professionals [24]. It has high reliability and discriminative validity for differentiating focal from generalized seizures [24]. Given the variability of epilepsy profiles in children with CZS [12], the use of a screening questionnaire to assist in differentiating focal from generalized seizures is important for optimizing antiseizure medication, especially if EEG is not available or is cost-prohibitive. In our case study, the neurophysiological data was concordant with neuroimaging findings and parent-reported seizure features and increased confidence in diagnosis of a focal epilepsy syndrome.

Global neurodevelopmental delays and suboptimal physical growth were apparent in our patient at two years of age, which is a common finding among children with CZS and microcephaly [31]. However, there is a wide spectrum of neurodevelopmental outcomes in CZS, with evidence for normal neurodevelopment in some children, even if microcephaly is present [32]. Neurodevelopmental delays are common in children with CZS and severe and frequent seizures [13]. The presence of epilepsy is associated with lower cognitive ability in children with microcephaly, independent of CZS [33]. Development of fine motor skills (such as hand-eye coordination) and gross motor skills (such as the ability to walk and maintain endurance) are significantly delayed in children with CZS and uncontrolled seizures [13]. Additionally, previously acquired motor skills can regress with frequent seizures [34]. Early and effective treatment can improve developmental trajectories [35]. Although epilepsy has not been formally investigated as a risk factor for abnormal neurodevelopment in CZS, these findings suggest that optimizing antiseizure medication to obtain seizure freedom can minimize the adverse impact of compromised neurodevelopment in children with CZS.

4. Conclusion

This case highlights the presence of focal seizures in a child with CZS and illustrates how a screening questionnaire and teleEEG platform can be used to augment epilepsy care in ZIKV-endemic regions, in close collaboration with epilepsy specialists.

Ethical statement

We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: SB reports support from Bio-Signal Group Co. and the following patents pending: 61/554,743; 13/284,886. None of the other authors have any conflicts of interest to disclose.

Acknowledgements

The authors would like to extend their gratitude to the participants involved in this study and to the Grenada Ministry of Health for their support. We acknowledge funding support from SGU/WINDREF GSP-SRGI-18009 (KB); USAID AID-OAA-A-14-00028 (KB, RW, DL), NIH R21HD093551-01 (RW, BL, MF), and Stanford Maternal Child Health Research Institute (ADL).

References

- [1] Rasmussen SA, Jamieson DJ, Honein MA, Peterson LR. Zika virus and birth defects – Reviewing the evidence for causality. *N Engl J Med* 2016;374:1981–7.
- [2] Bayer A, Lennemann NJ, Ouyang Y, Bramley JC, Morosky S, Marques Jr ET, et al. Type III interferons produced by human placental trophoblasts confer protection against Zika virus infection. *Cell Host Microbe* 2016;19(5):705–12.
- [3] Sheridan MA, Yunusov D, Balaraman V, Alexenko AP, Yabe S, Verjovskii-Almeida S, et al. Vulnerability of primitive human placental trophoblast to Zika virus. *PNAS* 2017;114(9):E1587–96.
- [4] Strafela P, Vizjak A, Mraz J, Pizem J, Tul N, Zupanc TA, et al. Zika virus-associated microcephaly: A thorough description of neuropathologic findings in the fetal central nervous system. *Arch Pathol Lab Med* 2017;141(1):73–81.
- [5] Tang H, Hammack C, Ogden SC, Wen Z, Qian X, Li Y, et al. Zika virus infects human cortical neural progenitors and attenuates their growth. *Cell Stem Cell* 2016;18(5):587–90.
- [6] de Fatima Vasco Aragao M, van der Linden V, Brainer-Lima AM, Coeli RR, Rocha MA, da Silva PS, et al. Clinical Features and Neuroimaging (CT and MRI) Findings in Presumed Zika Virus Related Congenital Infection and Microcephaly: Retrospective Case Series Study *BMJ* 2016;353:i1901.
- [7] Moore CA, Staples JE, Dobyns WB, Pessoa A, Ventura CV, Fonseca EBD, et al. Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians. *JAMA Pediatrics* 2017.
- [8] Aragao MFV, Holanda AC, Brainer-Lima AM, Petribu NCL, Castillo M, van der Linden V, et al. Nonmicrocephalic infants with congenital Zika syndrome suspected only after neuroimaging evaluation compared with those with microcephaly at birth and postnatally: How large is the Zika virus 'iceberg'? *Am J Neuroradiol* 2017;38(7):1427–34.
- [9] Oliveira-Filho J, Felzemburgh R, Costa F, Nery Jr N, Mattos A, Henriques DF, et al. Seizures as a complication of congenital Zika syndrome in early infancy. *Am J Trop Med Hygiene* 2018;98(6):1860–2.
- [10] da Silva AAM, Ganz JSS, Sousa PDS, Doriqui MJR, Ribeiro MRC, Branco MDRFC, et al. Early growth and neurologic outcomes of infants with probable congenital Zika virus syndrome. *Emerg Infect Dis* 2016;22(11):1953–6.
- [11] Alves LV, Paredes CE, Silva GC, Mello JG, Alves JG. Neurodevelopment of 24 children born in Brazil with congenital Zika syndrome in 2015: a case series study. *BMJ Open* 2018;8:e201304.
- [12] Van Der Linden H, Jr CMD, van der Linden V, Lacerda KM, Pessoa A, Carneiro ML, et al. Epilepsy profile in infants with congenital Zika virus infection. *N Engl J Med* 2018;379(9):891–2.
- [13] Pessoa A, van der Linden V, Yeargin-Allsopp M, Carvalho MDCG, Ribeiro EM, Van Naarden BK, et al. Motor abnormalities and epilepsy in infants and children with evidence of congenital Zika infection. *Pediatrics* 2018;141(2):167–79.
- [14] Blackmon K, Waechter R, Landon B, Noël T, Macpherson C, Donald T. Epilepsy surveillance in normocephalic children with and without prenatal Zika virus exposure. *PLOS Neglected Tropical Diseases* 2020 (In Press).
- [15] Baca CB, Barry F, Vickrey BG, Caplan R, Berg AT. Social outcomes of young adults with childhood-onset epilepsy: A case sibling control study. *Epilepsia* 2017;58(5):781–91.
- [16] Nielsen-Saines K, Brasil P, Kerin T, Zilton V, Gabaglia CR, Damasceno L, et al. Delayed childhood neurodevelopment and neurosensory alterations in the second year of life in a prospective cohort of ZIKV-exposed children. *Nat Med* 2019;25:1213–7.
- [17] de Oliveira N, Souza I, Frost PS, Franca JV, Nascimento-Viana JB, Neris RLS, et al. Acute and chronic neurological consequences of early-life Zika virus infection in mice. *Sci Transl Med* 2018;10(444).
- [18] Krauss G, Sandy S, Corbin DO, Bird-Compton J, Jack F, Nelson B, et al. Epilepsy Care in the southern Caribbean. *Epilepsy Behav* 2015;51:267–72.
- [19] Grossi-Soyster EN, Cook EAJ, de Glanville WA, Thomas LF, Krystosik AR, Lee J, et al. Serological and spatial analysis of alphavirus and flavivirus prevalence and risk factors in a rural community in western Kenya. *PLoS Negl Trop Dis* 2017;11(10):e0005998.

- [20] Zhang B, Pinsky BA, Ananta JS, Zhao S, Arulkumar S, Wan H, et al. Diagnosis of Zika virus infection on a nanotechnology platform. *Nat Med* 2017;23(5):548–50.
- [21] World Health Organization. Screening, assessment and management of neonates and infants with complications associated with Zika virus exposure in utero. WHO; 2016.
- [22] Fernandes M, Villar J, Stein A, et al. INTERGROWTH-21st project international INTER-NDA standards for child development at 2 years of age: an international prospective population-based study. *BMJ Open* 2020;10(6):e035258.
- [23] Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. *Epilepsia* 2014;55(4):475–82.
- [24] Patel AA, Ciccone O, Njau A, Shanungu S, Grollnek AK, Fredrick F, et al. A pediatric epilepsy diagnostic tool for use in resource-limited settings: a pilot study. *Epilepsy Behav* 2016;59:57–61.
- [25] Ibrahim ZH, Chari G, Abdel Baki S, Bronshtein V, Kim MR, Weedon J, et al. Wireless multichannel electroencephalography in the newborn. *J Neonatal Perinatal Med.* 2016;9(4):341–8.
- [26] Grant AC, Abdel-Baki SG, Omurtag A, Sinert R, Chari G, Malhotra S, et al. Diagnostic accuracy of microEEG: a miniature, wireless EEG device. *Epilepsy Behav.* 2014;34:81–5. <https://doi.org/10.1016/j.yebeh.2014.03.015>.
- [27] Omurtag A, Baki SG, Chari G, Cracco RQ, Zehtabchi S, Fenton AA, et al. Technical and clinical analysis of microEEG: a miniature wireless EEG device designed to record high-quality EEG in the emergency department. *Int J Emerg Med* 2012;5:35. <https://doi.org/10.1186/1865-1380-5-35>.
- [28] Birbeck GL, Herman ST, Capparelli EV, Dzinjalama FK, Abdel Baki SG, Mallewa M, et al. A clinical trial of enteral Levetiracetam for acute seizures in pediatric cerebral malaria. *BMJ Paediatr.* 2019;19(1):399. <https://doi.org/10.1186/s12887-019-1766-2>.
- [29] Van Den Pol AN, Mao G, Yang Y, Ornaghi S, Davis JN. Zika virus targeting in the developing brain. *J Neurosci* 2017;37(8):2161–75.
- [30] Cugola FR, Fernandes IR, Russo FB, et al. The Brazilian Zika virus strain causes birth defects in experimental models. *Nature* 2016;534(7606):267–71.
- [31] de Franca TLB, Medeiros WR, de Souza NL, Longo E, Pereira SA, Franca TBDO, et al. Growth and development of children with microcephaly associated with congenital Zika virus syndrome in Brazil. *Int J Environ Res Public Health* 2018;15(9):1990.
- [32] de Carvalho AL, Brites C, Taguchi TB, Pinho SF, Campos G, Lucena R. Congenital Zika virus infection with normal neurodevelopmental outcome, Brazil. *Emerg Infect Dis* 2018;24(11):2128–30.
- [33] Abdel-Salam G, Halász A, Czeizel A. Association of epilepsy with different groups of microcephaly. *Dev Med Child Neurol* 2000;42(11):760–7.
- [34] Wheeler AC. Development of infants with congenital Zika syndrome: what do we know and what can we expect?. *Pediatrics* 2018;141(Supplement 2):S154–60.
- [35] Lockrow J, Tully H, Saneto RP. Epileptic spasms as the presenting seizure type in a patient with a new “O” of TORCH, congenital Zika virus infection. *Epilepsy Behav Case Rep* 2018;11:1–3.